Provided by Tiger Trade Technology Pte. Ltd.

SCYNEXIS Inc

4.08
-0.1400-3.32%
Post-market: 4.090.0100+0.25%17:17 EDT
Volume:119.55K
Turnover:489.03K
Market Cap:40.52M
PE:-3.06
High:4.23
Open:4.19
Low:4.02
Close:4.22
52wk High:9.12
52wk Low:3.53
Shares:9.93M
Float Shares:7.51M
Volume Ratio:0.55
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3352
EPS(LYR):-1.3793
ROE:-18.38%
ROA:-20.82%
PB:0.61
PE(LYR):-2.96

Loading ...

Scynexis - Ivor Macleod Retires as CFO Effective September 9, 2026

THOMSON REUTERS
·
Sep 10

Scynexis Announces Appointment of Sanjay Subramanian as Chief Financial Officer

THOMSON REUTERS
·
Sep 10

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

GlobeNewswire
·
Sep 10

SCYNEXIS to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Scynexis Grants New Senior Director Stock Options for 20,000 Shares at USD 5.26

Reuters
·
Aug 26

Scynexis Announces Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 26

Scynexis is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 13

Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change

Reuters
·
Aug 12

Scynexis Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Codexis Q2 Net Loss Narrows, Helped by Lower Operating Expenses

Reuters
·
Aug 12

Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities

Reuters
·
Aug 11

SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate

Benzinga Earnings
·
Aug 11

Scynexis Q2 Swings to Profit on Warrant Adjustment; Advances Drug Studies

Reuters
·
Aug 11

Scynexis - May Receive up to $146 Mln in Annual Net Sales Milestones & Net Royalties in the Low to Mid-Single Digit Range

THOMSON REUTERS
·
Aug 11

Scynexis Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 11

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Scynexis Q2 Net Income Swings to USD 7.4 Million; Revenue Drops 82.8% to USD 235,000

Reuters
·
Aug 11

Scynexis Inc Expected to Post a Loss of 51 Cents a Share - Earnings Preview

Reuters
·
Aug 08

NASDAQ Trade Halt Volatility Trading Pause at 11:47 Am

Reuters
·
Jul 31

Scynexis Initiates Phase 1 Study of Scy-770, a Novel Ampk Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd)

Reuters
·
Jul 06